Boehringer Ingelheim Corporation Release: A New Era for Patients with Atrial Fibrillation - Dabigatran Etexilate at the Forefront
INGELHEIM, Germany--(BUSINESS WIRE)--The European Society of Cardiology (ESC) today issued revised practice guidelines for the management of atrial fibrillation (AF), including guidance on the role of a novel oral treatment, dabigatran etexilate, for the prevention of stroke and systemic embolism in patients with atrial fibrillation (AF).